An unpopular vaccine still sparked mistrust. The person we now call Vaxzevria is still talking about. Nine new cases of atypical blood clots (thrombosis) and two cases of coagulation disorders related to AstraZeneca’s Covid-19 vaccine, with an additional four deaths, occurred in France between April 2 and April 8, according to health authorities.
The French Medicines Agency (ANSM) reported on Friday that since the start of vaccination with this vaccine, there have been “23 cases, including 8 deaths in total” of rare thrombosis and coagulation abnormalities that have occurred in France. These cases are still very rare: in total, more than 2,725,000 injections were given on April 8 with the AstraZeneca vaccine.
Average age 62
Of these, “21 cases were associated with venous cerebral thrombosis and / or gastrointestinal thrombosis and two were with isolated intravascular thrombosis (DIC)”. These two bleeding disorders (DICs) are part of this new vaccine monitoring update.
limited offer. Two months for € 1, no obligation
The nine new cases of rare blood clots involved people providing a “different picture” of the previously announced cases, ANSM notes. Age of patients “higher”: “They are four women and five older men (average age 62) and had more clotting in the gastrointestinal tract.”
However, due to the rare cases of blood clots that have been detected in Europe and France, since March 19, the AstraZeneca vaccine has been given to people 55 years of age and over in the country. “This is not good news,” but “this risk is very low,” he stresses franceinfo Matteo Mollimar, Head of the Department of Pharmacology at Purdue University Hospital. “The risk of 1 in 100,000 people facing a 1% or 1 in 1,000 people at risk of dying from Covid-19 who still have favorable risk benefits (…) The reason will be that ‘We continue to vaccinate as long as we do not have enough.’ RNA vaccines have less risk. But it is difficult politically. ”
Monitor “two possible signals”
“These new items will be shared with the European Medicines Agency (EMA),” as part of the European assessment of these blood problems, according to health authorities. The previous assessment was 12 cases of stroke, including 4 deaths, since the start of vaccination.
In addition, the agency reported two “signals” that would be “subject to special surveillance.” “Two possible signs” were identified “after five new cases of facial paralysis for a total of 15 cases since the start of vaccination” and neurological damage that people are “in the process of recovering from”, ANSM specifies.
These latest attacks represent three new cases of “acute radiculopathy (including Guillain-Barré syndrome) for a total of five cases since the start of vaccination,” according to this new assessment.
Opinions
Warning
State practice
Strategist look
The best of the world
